➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
McKinsey
Johnson and Johnson
Mallinckrodt
Boehringer Ingelheim

Last Updated: July 27, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,690,837


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,690,837 protect, and when does it expire?

Patent 8,690,837 protects BYDUREON PEN and is included in one NDA.

Protection for BYDUREON PEN has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has five patent family members in four countries.

Summary for Patent: 8,690,837
Title:Mixing device for a two-chamber ampoule
Abstract: A device for administering a product (e.g. a medicinal or therapeutic substance), the device including a receptacle for the product or constituents of the product and a casing, wherein the receptacle and casing are engaged, and an outer sleeve, wherein the casing can be moved relative to the receptacle into the outer sleeve.
Inventor(s): Mori; Kevin (Burgdorf, CH), Kaenel; Celine (Zurich, CH), Drunk; Annette (Bern, CH), Hirschel; Jurg (Aarau, CH), Moser; Ulrich (Heimiswil, CH), Tschirren; Markus (Kirchberg, CH), Wymann; Martin (Liebefeld, CH), Harris; Scott (San Diego, CA), Ryan; Patrick J. (Boston, MA), Pidgeon; Andrew D. (Cambridge, GB), Tuckwell; Jonathan D. (Cambridge, GB), Mann; Richard (Cambridge, GB)
Assignee: TecPharma Licensing AG (Burgdorf, CH)
Application Number:12/951,637
Patent Claim Types:
see list of patent claims
Device;

Drugs Protected by US Patent 8,690,837

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca Ab BYDUREON PEN exenatide synthetic FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 022200-002 Feb 28, 2014 DISCN Yes No ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,690,837

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany10 2008 025 002May 24, 2008

International Family Members for US Patent 8,690,837

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Germany 102008025002 ⤷  Try it Free
European Patent Office 2300080 ⤷  Try it Free
Taiwan 200948407 ⤷  Try it Free
Taiwan I411453 ⤷  Try it Free
World Intellectual Property Organization (WIPO) 2009143640 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Medtronic
Express Scripts
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.